| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 14.97 | -0.14 (-0.93%) | 8.64 - 16.80 | 1.3 million (Below Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 15.11 |
|---|---|
| Previous Close | 15.11 |
| Day's Range | 14.74 - 15.48 |
| Market Cap | 729.4M |
| Avg Volume (10 Day) | 2.1M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.2 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Optimer Pharmaceuticals Appoints Eric Sirota as Chief Operating Officer
PR Newswire - Monday 05/13/2013 4:04 PM ET
Optimer Reports First Quarter 2013 Financial Results
PR Newswire - Thursday 05/09/2013 4:02 PM ET
Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2013 Financial Results
PR Newswire - Thursday 05/02/2013 8:00 AM ET
DIFICIDĀ® (fidaxomicin) Tablets Approved in Australia
PR Newswire - Friday 04/26/2013 8:00 AM ET
| OPTR | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 18.32% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.00 | |
| LT Debt/Equity | 0.00 | |
| Earnings Yield | -- | |
| Price/Sales | 6.84 |
| Company | Last | Change |
|---|---|---|
| Ambit Biosciences Corp | 6.75 | -8.66% |
| China Biologic Products Inc | 26.48 | +1.30% |
| Achillion Pharmaceuticals Inc | 7.77 | +2.78% |
| Array Biopharma Inc | 5.89 | +3.51% |
| Exact Sciences Corp | 10.56 | -2.40% |
Data is delayed by at least 15 min.